$180.00
0.90% day before yesterday
NYSE, Dec 24, 10:51 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock price

$180.00
+2.94 1.66% 1M
+9.25 5.42% 6M
+25.03 16.15% YTD
+25.06 16.17% 1Y
+45.59 33.92% 3Y
+90.15 100.33% 5Y
+113.79 171.86% 10Y
NYSE, Closing price Wed, Dec 25 2024
+0.00 0.00%
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

Key metrics

Market capitalization $318.09b
Enterprise Value $381.92b
P/E (TTM) P/E ratio 62.77
EV/FCF (TTM) EV/FCF 24.51
EV/Sales (TTM) EV/Sales 6.88
P/S ratio (TTM) P/S ratio 5.73
P/B ratio (TTM) P/B ratio 52.73
Dividend yield 3.49%
Last dividend (FY24) $6.29
Revenue growth (TTM) Revenue growth 0.72%
Revenue (TTM) Revenue $55.53b
EBIT (operating result TTM) EBIT $17.00b
Free Cash Flow (TTM) Free Cash Flow $15.59b
Cash position $7.29b
EPS (TTM) EPS $2.87
P/E forward 45.72
P/S forward 5.68
EV/Sales forward 6.82
Short interest 1.09%
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a AbbVie forecast:

19x Buy
61%
12x Hold
39%

Analyst Opinions

31 Analysts have issued a AbbVie forecast:

Buy
61%
Hold
39%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
55,533 55,533
1% 1%
100%
- Direct Costs 16,733 16,733
5% 5%
30%
38,800 38,800
1% 1%
70%
- Selling and Administrative Expenses 5,536 5,536
212% 212%
10%
- Research and Development Expense 7,939 7,939
5% 5%
14%
25,325 25,325
15% 15%
46%
- Depreciation and Amortization 8,325 8,325
5% 5%
15%
EBIT (Operating Income) EBIT 17,000 17,000
20% 20%
31%
Net Profit 5,081 5,081
22% 22%
9%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Positive
The Motley Fool
about 2 hours ago
If you're looking for attractive dividend-paying stocks, that's a smart move. If you're not, perhaps reconsider -- because:
Positive
Seeking Alpha
2 days ago
2024 is going out with a bang as mystery drones, Federal Reserve hawkishness, and quantum stocks dominate headlines. It's time to look towards 2025 after another banner year for stocks. Here are four stocks in timely, tremendous industries to keep on your radar.
Positive
The Motley Fool
3 days ago
With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (ABBV 2.37%) is a powerhouse big pharma that has a lot of upside to offer to investors.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 50,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today